Back to Pulse
Build this in Pulse Download 10-page report
AssayIQ PulseDETAILED CASE STUDY / 10-PAGE EDITION

LABORATORY PERFORMANCE & OPERATING IMPROVEMENT

Finding the delay.
Testing a better way.

A complete operating story: the baseline, the exceptions, the analysis, the investment questions and the work that comes next.

10,080 synthetic test events3 labs · 3 shifts · 5 assays28 days · October 2026

Fictional network · synthetic results · separately labeled planning assumptions

01 / EXECUTIVE SNAPSHOT

Finding the delay. Testing a better way.

A detailed AssayIQ Pulse demonstration of how a regional laboratory network can turn operational data into a focused improvement agenda, an accountable action plan and a more informed investment discussion.

Mean TAT53.4 min

19.5% lower than baseline

66.4 min baseline
Within local TAT target75.1%

32.0 pp vs baseline

3,787 / 5,040 follow-up events
90th percentile TAT66.4 min

19.3 min below baseline

85.7 min baseline
Rerun events3.1%

-3.1 pp vs baseline

158 / 5,040 follow-up events

The question

Where is turnaround time being lost, which assays still need attention, and what evidence should leadership review before changing staffing, workflows or equipment? This fictional network brings those questions into one reporting process.

Figure 1. Mean turnaround by process phase

Two 14-day synthetic populations, 5,040 events each. Phase totals are calculated from event records, not from rounded labels.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
02 / CONTEXT & OPERATING PRIORITIES

One network. Several different operating questions.

The demonstration uses three fictional laboratories to show how a common metric framework can support local action without hiding variation behind a network average.

Demonstration network profile
DimensionIncluded scope
SitesCentral Lab, North Lab and West Lab
Work areasChemistry/immunoassay and hematology event labels
Instrument labels12 across the network; 4 per site
Shifts and assays3 shifts; Potassium, Troponin, CBC, TSH and Lactate
Review windowOctober 1-28, 2026; two equal 14-day periods
Event population10,080 original test events; 360 per day

The operating brief

  1. 01

    Improve the predictability of turnaround while keeping reruns and local quality concerns visible.

  2. 02

    Identify the assays and shifts that warrant a focused review rather than applying a network-wide fix.

  3. 03

    Understand workload and test a capacity hypothesis before making a purchasing commitment.

  4. 04

    Bring methods, assumptions, actions and decision owners into the same leadership discussion.

Site performance: baseline (B) versus follow-up (F); means in minutes
LabMean BMean FTarget BTarget FAll events
Central Lab63.550.748.8%82.0%3,360
North Lab66.253.443.5%76.0%3,360
West Lab69.456.137.0%67.4%3,360
AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
03 / DATA FOUNDATION & IMPLEMENTATION

Build confidence in the baseline before interpreting change.

A credible improvement report begins with consistent definitions and a documented population. The public Pulse tool demonstrates the calculation path; a client deployment requires an agreed source mapping and local acceptance review.

Data review for the synthetic event population
CheckFindingMeaning
Event count10,080 rowsOne original test event per row
Unique event tokens10,080 unique IDsNo duplicate event tokens
Validity / exclusionsAll rows valid / 0 excludedNo silently discarded records
Date coverage28 dates / 360 events dailyComplete constructed calendar
Period mix5,040 events in each periodEqual site, shift and assay counts
Source captureNot independently verifiableNo LIS completeness claim

Proposed implementation sequence

  1. 01

    Define: agree the operational question, local targets, source fields, period boundaries and accountable sponsor.

  2. 02

    Map and reconcile: compare accepted exports with source-system control totals; review missing and duplicate events.

  3. 03

    Review: examine phase-level TAT, the long tail, site/shift variation and assay-specific target misses.

  4. 04

    Act and sustain: select one test of change, assign an owner, review guardrails and document the next decision.

Decision boundaries

The public version uses CSV data and local browser calculations. Automatic feeds, secure hosted access, production security controls and local validation must be scoped before deployment. The synthetic period change was built into the generator; it is not attributed to the proposed workflow actions.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
04 / TURNAROUND TIME & ASSAY EXCEPTIONS

The average improves. The assay detail changes the priority.

Across the synthetic network, mean turnaround moves from 66.4 to 53.4 minutes and the 90th percentile moves from 85.7 to 66.4 minutes. Target attainment rises by 32.0 percentage points.

Figure 2. Daily mean and 90th percentile turnaround
Mean TATP90 TATMinutes per original event
0306090120Follow-up10-0110-0810-1510-2210-28

Minutes per original event; 360 events per date. The dashed boundary separates baseline from follow-up. This is a constructed change, not a measured intervention effect.

Assay review: baseline (B) versus follow-up (F); means in minutes
AssayMean BMean FTarget BTarget FF events
Potassium64.051.542.3%83.7%1008
Troponin65.251.738.8%82.5%1008
CBC64.251.340.3%84.0%1008
TSH73.861.286.6%99.8%1008
Lactate64.651.27.5%25.6%1008
AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
05 / WORKLOAD & WORKFLOW TIMING

Put the time of demand beside the time of disruption.

An hourly workload view can help a team decide when to investigate transport runs, receiving handoffs, staffing coverage or maintenance. This case adds an explicitly constructed hourly allocation to demonstrate that review.

Figure 3. Illustrative hourly event profile
WeekdayWeekendAverage events per day at each hour
01020304000:0004:0008:0012:0016:0020:0023:00

Average events per calendar day by hour. Weekday = 20 days; weekend = 8 days. Hours are deterministically allocated within shifts and are not recorded timestamps from the base CSV.

Shift review: baseline (B) versus follow-up (F); means in minutes
ShiftMean BMean FTarget FReruns FAll events
Day64.451.579.3%2.5%3,360
Evening66.553.574.6%3.6%3,360
Night68.355.271.5%3.3%3,360

An operating experiment to consider

In the constructed weekday profile, demand peaks at 09:00. A team could compare that demand with actual maintenance and availability logs, then consider a different service window or receiving handoff. No maintenance change is modeled as having occurred. Manufacturer instructions, staffing and clinical coverage remain constraints.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
06 / INSTRUMENT WORKLOAD & CAPACITY

Test a capacity hypothesis before buying a solution.

Test counts show workload distribution. They do not establish instrument utilization. This separate planning scenario adds scheduled, maintenance and busy minutes for four fictional Central Lab instruments.

Figure 4. Modeled busy-time utilization and 15% demand stress
Modeled baseline15% demand stress
CHEM-1A
26.1%
30.0%
CHEM-1B
25.2%
28.9%
HEM-1A
15.7%
18.0%
HEM-1B
15.2%
17.5%
0%50%100%

Utilization = busy minutes / (scheduled minutes minus maintenance). The stress case assumes busy time scales linearly with demand. These are constructed instrument-log inputs, not measured device performance.

Central Lab capacity inputs: 28-day planning scenario
InstrumentEventsAvailable minBusy minModeled use+15% load
CHEM-1A1,34438,64010,08026.1%30.0%
CHEM-1B1,34438,6409,72025.2%28.9%
HEM-1A33638,6406,04815.7%18.0%
HEM-1B33638,6405,88015.2%17.5%

The decision the scenario supports

The model suggests a question worth checking: can existing equipment accommodate a defined increase in demand? It does not establish peak-hour headroom, assay-menu capacity, uptime, staffing availability or resilience after a device failure. Parallel processing and assay-specific constraints require local review.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
07 / RERUNS, RELEASE & QUALITY GUARDRAILS

Read the improvement signal alongside the unresolved work.

Rerun flags fall from 314 to 158 events, a 49.7% relative difference across equal populations. Automatic release moves from 68.1% to 85.6%. Neither change alone establishes clinical quality.

Figure 5. Follow-up TAT distribution

5,040 original events. Bin boundaries are explicit and mutually exclusive; counts reconcile to the follow-up population.

Balanced quality and release review
MeasureBaselineFollow-upInterpretation
Rerun rate6.2%3.1%Reason and necessity still require review
Rerun events314158At least one rerun; not a run count
Automatic release68.1%85.6%Not proof that release rules are safe
Within local target43.1%75.1%Assay exceptions remain visible

Guardrails for a real pilot

  1. 01

    Classify repeat work by reason before deciding it is avoidable; clinically necessary repeats remain necessary.

  2. 02

    Review QC, calibration, specimen quality, critical-result escalation and amended reports using approved local systems.

  3. 03

    Change autoverification or release rules only through the laboratory's approved validation and authorization process.

  4. 04

    Keep assay-specific target misses and source-data gaps open until the responsible leader reviews them.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
08 / FINANCIAL INTERPRETATION

Separate reagent expense, staff capacity and cash savings.

A useful business case makes its assumptions visible. This scenario models only incremental reagent expense and a stated staff-time assumption. It does not report realized cash savings or a return on investment.

Cost and capacity bridge: two 14-day periods
ItemBaselineFollow-upDifference / basis
Repeat reagent proxy$709.95$389.45$320.50 lower
Rerun-flagged events314158156 fewer flags
Assumed work per flag4 minutes4 minutesPlanning input, not a time study
Modeled staff capacity20.9 h10.5 h10.4 hours
Capacity value at $45/h$942.00$474.00$468.00; not cash saved
Confirmed avoided capitalNot establishedNot establishedNo amount recognized
Sensitivity to staff minutes per flagged event
Minutes / flagCapacity hoursCapacity value at $45/h
25.2$234.00
410.4$468.00
615.6$702.00

What finance would need before a buying decision

Verify unit costs, rerun multiplicity, actual hands-on time, implementation expense, ongoing support and any costs required to realize a cash reduction. Released staff time can support other work without reducing payroll. A 14-day synthetic comparison should not be annualized into a promised savings figure.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
09 / IMPLEMENTATION & EFFECTIVENESS PLAN

Turn the report into an owned 30/60/90-day review.

The actions below are proposed demonstration work, not completed client actions. Each has an accountable role, a review horizon and evidence needed for a decision.

Proposed action register
HorizonOwner roleActionEvidence for review
Day 30Lab operations leadConfirm source completeness and the Lactate sample pathwayReconciled counts; timestamp map; local target approval
Day 30Quality leadClassify rerun causes and review release-rule governanceReason-coded sample; QC and escalation review
Day 60Shift leadTest one approved receiving or handoff changeComparable pre/post populations; workload and quality guardrails
Day 60Technical leadReconcile actual maintenance and capacity logsPeak-hour queues; device availability; contingency assessment
Day 90Lab director + financeReview effectiveness and approve next scopeSustained measures; full-cost model; unresolved-risk register

Decision gates

  1. 01

    Data gate: agreed definitions, reconciled control totals and documented exclusions before interpretation.

  2. 02

    Pilot gate: a limited change, an accountable owner and local approval before operational rollout.

  3. 03

    Effectiveness gate: compare like periods and assay mix; review more than one summary average.

  4. 04

    Scale gate: expand only after leaders review sustained performance, quality effects, staff workload and the full commercial scope.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑
10 / METHODS, SOURCES & REPRODUCTION

Make the evidence easy to inspect.

The event population, calculations and supplemental assumptions are available separately so that a reviewer can reproduce the report and distinguish data-derived findings from constructed planning inputs.

Metric definitions
MetricDefinition
Total TATpre_min + analytic_min + post_min; minutes per original event
Mean / P90Event-weighted mean; P90 linearly interpolated at (n-1) x 0.9
Within targetCount(TAT <= target_min) / original events x 100
Rerun / automatic releaseSum of the corresponding 0/1 flag / original events x 100
Percentage-point changeFollow-up percentage minus baseline percentage
Relative mean TAT change(Baseline mean - follow-up mean) / baseline mean x 100
Repeat reagent proxySum(rerun flag x reagent_cost); one extra run assumed
Modeled utilizationBusy / (scheduled - maintenance) minutes x 100

Scope and limitations

Source: deterministic AssayIQ synthetic event generator v1, 10,080 events, no patient data. Baseline: October 1-14; follow-up: October 15-28, 2026. Local example targets: Lactate 45 minutes; Potassium, Troponin and CBC 60 minutes; TSH 90 minutes. These are illustrative goals, not clinical or accreditation standards. Source-system completeness, actual intervention effects and clinical outcomes are not established.

Supplemental assumptions

Hourly event allocation uses fixed shift weights and reconciles to the original daily totals. Capacity uses invented instrument-log inputs: 40,320 scheduled minutes and 1,680 maintenance minutes per device over 28 days, plus stated busy minutes. Finance assumes four staff minutes per rerun flag and $45 per loaded staff hour. The 15% demand stress assumes a linear busy-time response.

Reference and independence

Roche's M Health Fairview case study was consulted as a benchmark for report depth and structure. Its customer results, quotations and endorsements are not used as AssayIQ results. NAVIFY is a Roche trademark. AssayIQ Global is independent and is not affiliated with Roche or M Health Fairview.

AssayIQ-created demonstration · Synthetic dataBack to report navigation ↑

THE EVIDENCE PACKAGE

Reproduce the numbers.
Inspect the assumptions.

The event export works with the public Pulse CSV importer. Hourly allocations, capacity inputs and financial assumptions are supplied separately so they cannot be mistaken for observed event fields.

Event dataset10,080 synthetic rows · CSVPlanning inputs & report calculationsStructured scenario assumptions · JSONComplete case study10 pages · Branded PDFReport-depth referenceRoche / M Health Fairview · independent external case

Give your leadership a clearer operating picture.

Discuss your first report